Drilldown: Medicines
Medicines > fda max 
:
10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) or
20 mg/d
& duration:
24 hours
:
10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) or
20 mg/d
& duration:
24 hours Use the filters below to narrow your results.
generic:
classes:
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antimuscarinics|Antimuscarinic (M3-selective)]] (1) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) ·
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1)
mechanism:
'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
starting dose:
preparations:
fda max: (Click arrow to add another value)
routes:
onset:
duration: (Click arrow to add another value)
halflife:
bioavailability:
Showing below up to 2 results in range #1 to #2.